Dr. William W. Oneill, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 28
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME173217 · MI license 4301039889 -
Interventional Cardiology Physician
FL license ME0097328 · MI license 4301039889
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 28
- Services billed
- 57
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 148 | 116 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 109 | 88 |
| Established patient office or other outpatient visit, 40-54 minutes | 36 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 34 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Naples, FL | 53 |
| Atorvastatin Calcium Other prescribers in Naples, FL | 26 |
| Ezetimibe Other prescribers in Naples, FL | 24 |
| Metoprolol Succinate Other prescribers in Naples, FL | 19 |
| Repatha Pushtronex (evolocumab) Other prescribers in Naples, FL | 19 |
| Potassium Chloride Other prescribers in Naples, FL | 17 |
| Eliquis (apixaban) Other prescribers in Naples, FL | 14 |
| Rosuvastatin Calcium Other prescribers in Naples, FL | 13 |
| Repatha Syringe (evolocumab) Other prescribers in Naples, FL | 12 |
| Repatha Sureclick (evolocumab) Other prescribers in Naples, FL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 27 payments worth $44,961 in total to this clinician.
| Tendyne Holdings, Inc. | $19,685 |
|---|---|
| Zoll Circulation Inc | $14,564 |
| Abiomed | $9,762 |
| Edwards Lifesciences Corporation | $587 |
| Angiodynamics, Inc. | $189 |
| Teleflex LLC | $175 |
| Consulting Fee | $22,488 |
|---|---|
| Acquisitions | $19,685 |
| Food and Beverage | $2,171 |
| Travel and Lodging | $618 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tendyne Holdings, Inc. Jun 12, 2025 | AcquisitionsCompany’s descriptionEscrow release associated with acquisition EMS TEN1 Payout - Event 2 Allocation - June 12 2025 | $19,685 |
| Zoll Circulation Inc Dec 29, 2025 | Consulting Fee TherOx DS2 Console; Catheter; Downstream Cartridge · TherOx Therapy | $7,000 |
| Abiomed Jun 23, 2025 | Consulting Fee | $6,338 |
| Zoll Circulation Inc Mar 6, 2025 | Consulting Fee TherOx DS2 Console; Catheter; Downstream Cartridge · TherOx Therapy | $6,000 |
| Abiomed Feb 6, 2025 | Consulting Fee | $2,250 |
| Zoll Circulation Inc Aug 8, 2025 | Consulting Fee TherOx DS2 Console; Catheter; Downstream Cartridge · TherOx Therapy | $900 |
| Abiomed Aug 8, 2025 | Travel and Lodging travel to Danvers, MA · in-kind | $312 |
| Zoll Circulation Inc Feb 28, 2025 | Travel and Lodging TherOx DS2 Console; Catheter; Downstream Cartridge · TherOx Therapy · travel to Coral Gables, FL | $306 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $69,448 in research payments for these studies, mostly to the institutions running them.
- CLASP IIF (2018-07)
Edwards Lifesciences Corporation - ALLIANCE 2021-05
Edwards Lifesciences Corporation - To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients
Zoll Circulation Inc · Terminated · NCT02064959 - TRISCEND II Pivotal Trial 2020-05 CONTINUED ACCESS STUDY
Edwards Lifesciences Corporation - CLASP IID 2018-07
Edwards Lifesciences Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.